CN106795117B - 杂双环化合物及其用于治疗结核病的用途 - Google Patents

杂双环化合物及其用于治疗结核病的用途 Download PDF

Info

Publication number
CN106795117B
CN106795117B CN201580045974.4A CN201580045974A CN106795117B CN 106795117 B CN106795117 B CN 106795117B CN 201580045974 A CN201580045974 A CN 201580045974A CN 106795117 B CN106795117 B CN 106795117B
Authority
CN
China
Prior art keywords
group
fluoro
methoxy
dihydroquinolin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580045974.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106795117A (zh
Inventor
清水洋
川野芳和
石川俊平
植松幸崇
篠原俊夫
丝谷元宏
原口佳和
竹村勋
兼重笃谨
中井雄野
播口德充
林阳平
松本真
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54105947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106795117(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN106795117A publication Critical patent/CN106795117A/zh
Application granted granted Critical
Publication of CN106795117B publication Critical patent/CN106795117B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
CN201580045974.4A 2014-08-28 2015-08-28 杂双环化合物及其用于治疗结核病的用途 Active CN106795117B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014-174528 2014-08-28
JP2014174528 2014-08-28
PCT/JP2015/004371 WO2016031255A1 (en) 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis

Publications (2)

Publication Number Publication Date
CN106795117A CN106795117A (zh) 2017-05-31
CN106795117B true CN106795117B (zh) 2020-06-26

Family

ID=54105947

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580045974.4A Active CN106795117B (zh) 2014-08-28 2015-08-28 杂双环化合物及其用于治疗结核病的用途

Country Status (29)

Country Link
US (2) US10053446B2 (enExample)
EP (1) EP3186240B9 (enExample)
JP (1) JP6625612B2 (enExample)
KR (1) KR102418413B1 (enExample)
CN (1) CN106795117B (enExample)
AP (1) AP2017009788A0 (enExample)
AR (1) AR101704A1 (enExample)
AU (1) AU2015307873B2 (enExample)
BR (1) BR112017003231B1 (enExample)
CA (1) CA2959478C (enExample)
CY (1) CY1122286T1 (enExample)
DK (1) DK3186240T3 (enExample)
EA (1) EA038414B1 (enExample)
ES (1) ES2743788T3 (enExample)
HR (1) HRP20191486T2 (enExample)
HU (1) HUE045025T2 (enExample)
IL (1) IL250484B (enExample)
LT (1) LT3186240T (enExample)
MX (1) MX2017002312A (enExample)
MY (1) MY189098A (enExample)
NZ (1) NZ729064A (enExample)
PH (1) PH12017500290B1 (enExample)
PL (1) PL3186240T3 (enExample)
PT (1) PT3186240T (enExample)
SG (1) SG11201700882XA (enExample)
SI (1) SI3186240T1 (enExample)
TW (1) TWI687409B (enExample)
WO (1) WO2016031255A1 (enExample)
ZA (1) ZA201700916B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101704A1 (es) * 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd Compuestos heterocíclicos fusionados
JP6905506B2 (ja) * 2016-02-26 2021-07-21 大塚製薬株式会社 ピペリジン誘導体
KR20210021042A (ko) 2018-06-15 2021-02-24 카딜라 핼쓰캐어 리미티드 포유동물 감염 치료를 위한 신규한 화합물
JP2023085582A (ja) * 2020-05-11 2023-06-21 大塚製薬株式会社 ジヒドロキノリノン化合物の共結晶
WO2022039506A1 (ko) * 2020-08-19 2022-02-24 주식회사 미토이뮨테라퓨틱스 Ｍabc-r 감염에 의한 병적 염증 치료제로서의 미토콘드리아 표적 항산화제
CN116102537B (zh) * 2021-11-10 2024-10-01 四川大学 一种喹啉酮类衍生物及其制备方法和用途
CN116589448B (zh) * 2023-04-24 2025-10-28 西南交通大学 一种3,4-二氢喹啉酮衍生物及其应用
WO2025183017A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物
WO2025183016A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1878777A (zh) * 2003-10-31 2006-12-13 大塚制药株式会社 治疗结核病的2,3－二氢－6－硝基咪唑并[2,1－b]噁唑化合物
WO2010045987A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials
CN101891680A (zh) * 2004-06-24 2010-11-24 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
CN102131778A (zh) * 2008-07-10 2011-07-20 普洛希典有限公司 杂环gpcr激动剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
TWI347946B (en) 2002-10-11 2011-09-01 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound
GB0319150D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
AU2004285811B2 (en) * 2003-10-31 2008-06-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-B) oxazole compounds for the treatment of tuberculosis
JP4761756B2 (ja) * 2003-10-31 2011-08-31 大塚製薬株式会社 ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
EP1988077A4 (en) 2006-02-23 2009-09-02 Shionogi & Co NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS
RU2540860C2 (ru) 2009-07-31 2015-02-10 Глоубал Элаенс Фор Тб Драг Дивелопмент Нитроимидазооксазиновые и нитроимидазооксазольные аналоги и их применение
JP5916739B2 (ja) 2011-04-15 2016-05-11 大塚製薬株式会社 ６，７−ジヒドロイミダゾ［２，１−ｂ］［１，３］オキサジン化合物
AR101704A1 (es) * 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd Compuestos heterocíclicos fusionados
JP6905506B2 (ja) * 2016-02-26 2021-07-21 大塚製薬株式会社 ピペリジン誘導体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1878777A (zh) * 2003-10-31 2006-12-13 大塚制药株式会社 治疗结核病的2,3－二氢－6－硝基咪唑并[2,1－b]噁唑化合物
CN101891680A (zh) * 2004-06-24 2010-11-24 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
CN102131778A (zh) * 2008-07-10 2011-07-20 普洛希典有限公司 杂环gpcr激动剂
WO2010045987A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials

Also Published As

Publication number Publication date
CN106795117A (zh) 2017-05-31
MY189098A (en) 2022-01-25
PH12017500290B1 (en) 2023-07-19
CY1122286T1 (el) 2021-01-27
KR20170043644A (ko) 2017-04-21
HRP20191486T2 (hr) 2021-09-17
PT3186240T (pt) 2019-09-06
IL250484B (en) 2020-04-30
LT3186240T (lt) 2019-09-10
US20180312488A1 (en) 2018-11-01
AR101704A1 (es) 2017-01-04
US20170253576A1 (en) 2017-09-07
EP3186240A1 (en) 2017-07-05
EA038414B1 (ru) 2021-08-25
ZA201700916B (en) 2019-06-26
TWI687409B (zh) 2020-03-11
BR112017003231B1 (pt) 2022-10-11
WO2016031255A1 (en) 2016-03-03
CA2959478C (en) 2023-09-26
AU2015307873A1 (en) 2017-03-09
ES2743788T3 (es) 2020-02-20
EP3186240B9 (en) 2019-12-04
DK3186240T3 (da) 2019-08-26
HRP20191486T1 (hr) 2019-11-15
HUE045025T2 (hu) 2019-12-30
JP6625612B2 (ja) 2019-12-25
TW201609658A (zh) 2016-03-16
IL250484A0 (en) 2017-03-30
PL3186240T3 (pl) 2020-03-31
SG11201700882XA (en) 2017-03-30
BR112017003231A2 (pt) 2017-11-28
PH12017500290A1 (en) 2017-06-28
CA2959478A1 (en) 2016-03-03
SI3186240T1 (sl) 2019-10-30
NZ729064A (en) 2022-09-30
KR102418413B1 (ko) 2022-07-06
EA201790464A1 (ru) 2017-06-30
US10053446B2 (en) 2018-08-21
AP2017009788A0 (en) 2017-02-28
US10464926B2 (en) 2019-11-05
AU2015307873B2 (en) 2020-01-16
JP2017525697A (ja) 2017-09-07
EP3186240B1 (en) 2019-06-12
MX2017002312A (es) 2017-05-08

Similar Documents

Publication Publication Date Title
CN106795117B (zh) 杂双环化合物及其用于治疗结核病的用途
US20240368189A1 (en) Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators
TW202220970A (zh) 化合物及使用方法
KR101538179B1 (ko) 수용체 티로신 키나제 억제제로서의 이미다조[1,2-ａ]피리딘 화합물
US12404295B2 (en) (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
US20120225062A1 (en) Novel kinase inhibitors
EA024293B1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ с-kit КИНАЗЫ
TWI822754B (zh) 作為crhr2拮抗劑之稠合環狀脲衍生物
JP2024529181A (ja) ピラゾロピリジノン化合物
WO2016112088A1 (en) Aryloxyacetylindoles and analogs as antibiotic tolerance inhibitors
JP6976691B2 (ja) 医薬組成物
AU2006331676A1 (en) Nitroimidazole compounds
KR20150013148A (ko) 항균성 퀴놀린 유도체
OA18228A (en) Heterobicyclic compounds and their use for the treatment of tuberculosis.
HK1239683B (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
HK1239683A1 (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
HK1201520B (en) Antibacterial quinoline derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant